Business
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million NOVATO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2024. “Our strong financial performance in the second quarter was driven by growing revenue across our commercial therapies from increasing global demand, leading us to raise our total revenue guidance for this year,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “In the quarter, we also reported positive data from our Phase 1/2 study in Angelman syndrome, our Phase 2/3 study in osteogenesis imperfecta, and our Phase 3 study in GSDIa. We are in an excellent position to achieve additional key milestones in the second half of the year including initiating our Phase 3 Angelman study and filing for accelerated approval for UX111 in Sanfilippo syndrome type A.” Second Quarter 2024 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands), (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Crysvita Product sales$40,449 $16,884 $76,690 $38,118 Revenue in Profit-Share Territory 67,045 61,314 107,447 111,220 Royalty revenue in European Territory 6,176 4,816 12,118 9,698 Total Crysvita Revenue 113,670 83,014 196,255 159,036 Dojolvi 19,355 16,491 35,717 30,794 Mepsevii 6,145 8,439 12,756 16,919 Evkeeza 7,856 365 11,131 577 Daiichi Sankyo — — — 1,479 Total revenues$147,026 $108,309 $255,859 $208,805 Total RevenuesUltragenyx reported $147 million in total revenue for the second quarter of 2024, which represents 36% growth compared to the same period in 2023. Second quarter 2024 Crysvita revenue was $114 million, which represents 37% growth compared to the same period in 2023. This includes product sales of $40 million from Latin America and Turkey, which represents 140% growth compared to the same period in 2023. Dojolvi revenue in the second quarter 2024 was $19 million, which represents 17% growth compared to the same period in 2023. Evkeeza r...